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2010-2011 Influenza Season 
Week 12 ending March 26, 2011 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 12 (March 20-26, 2011), influenza activity in the United States decreased.  
o Of the 5,319 specimens tested by U.S. World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and 
reported to CDC/Influenza Division, 737 (13.9%) were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) has been at or above 
the epidemic threshold for the ninth consecutive week. 
o Twelve influenza-associated pediatric deaths were reported, bringing the season total to 89. 
Four of these deaths were associated with influenza B viruses; four were associated with 
2009 influenza A (H1N1) viruses; one was associated with influenza A (H3N2) virus, and 
three were associated with an influenza A virus for which the subtype was not determined. 
o The proportion of outpatient visits for influenza-like illness (ILI) was 2.0%, below the national 
baseline of 2.5%. Two of the 10 regions (Regions 2 and 10) reported ILI at or above region-
specific baseline levels. One state experienced high ILI activity; three states experienced 
low ILI activity; 46 states and New York City experienced minimal ILI activity, and the District 
of Columbia had insufficient data. 
o The geographic spread of influenza in 10 states was reported as widespread; 21 states 
reported regional influenza activity; the District of Columbia and 12 states reported local 
influenza activity, and Guam, Puerto Rico, the U.S. Virgin Islands and six states reported 
sporadic influenza activity. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative since October 3, 2010 (Week 40) 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of 
jurisdictions 
reporting 
regional or 
widespread 
activity§ 
A (H3) 
2009 A 
(H1N1) 
A 
(Subtyping not 
performed) 
B 
Pediatric 
Deaths 
Nation Normal 13.9% 32 of 54 15,565 9,843 10,857 12,595 89 
Region 1 Normal 32.3% 5 of 6 1,598 838 86 323 2 
Region 2 Elevated 19.7% 2 of 4 675 319 1,055 348 9 
Region 3 Normal 20.8% 3 of 6 2,820 2,480 816 836 10 
Region 4 Normal 10.6% 2 of 8 1,326 1,357 3,095 3,894 16 
Region 5 Normal 36.8% 4 of 6 1,809 1,335 354 1,065 16 
Region 6 Normal 9.9% 2 of 5 2,161 528 2,281 2,539 16 
Region 7 Normal 20.1% 2 of 4 675 529 275 646 1 
Region 8 Normal 18.8% 5 of 6 1,674 632 1,998 1,715 6 
Region 9 Normal 18.2% 4 of 5 1,847 1,123 737 1,116 11 
Region 10 Elevated 28.0% 3 of 4 980 702 160 113 2 
*HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, U.S. Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, 
SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; 
and Region 10: AK, ID, OR, WA). 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands. 
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U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington, D.C., report to CDC the number of respiratory specimens tested for influenza and 
the number positive by influenza type and subtype. The results of tests performed during the 
current week are summarized in the table below. 
 
 Week 12 
No. of specimens tested 5,319 
No. of positive specimens (%) 737 (13.9%) 
Positive specimens by type/subtype  
Influenza A 525 (71.2%) 
          A (2009 H1N1)   114 (21.7%)             
          A (subtyping not performed)          224 (42.7%) 
          A (H3)                187 (35.6%)     
Influenza B 212 (28.8%) 
 
All influenza types and subtypes have been identified at high levels this season and continue to 
circulate widely. The predominant virus has varied by week, region, and even between states within 
the same region. 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2010-11 Season 
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Aggregate Hospitalization and Death Reporting Activity (AHDRA): This system tracks weekly 
counts of laboratory-confirmed influenza-associated hospitalizations and deaths and was 
implemented on August 30, 2009, during the 2009 pandemic, and ended on April 4, 2010. AHDRA 
surveillance during the 2010-11 season is being continued on a voluntary basis, and 14 jurisdictions 
reported during week 12. From October 3, 2010 – March 26, 2011, 14,547 laboratory-confirmed 
influenza associated hospitalizations and 277 laboratory-confirmed influenza associated deaths 
were reported to CDC. 
  
Weekly Laboratory-Confirmed Influenza-Associated Hospitalizations and 
Deaths, National Summary, 2010-11 Season 
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Antigenic Characterization: CDC has antigenically characterized 1,468 influenza viruses [353 
2009 influenza A (H1N1) viruses, 626 influenza A (H3N2) viruses, and 489 influenza B viruses] 
collected by U.S. laboratories since October 1, 2010. 
2009 Influenza A (H1N1) [353] 
 Three hundred fifty-two (99.7%) of the 353 tested were characterized as 
A/California/7/2009-like, the influenza A (H1N1) component of the 2010-11 influenza 
vaccine for the Northern Hemisphere. One virus (0.3%) of the 353 tested showed 
reduced titers with antiserum produced against A/California/7/2009. 
 
Influenza A (H3N2) [626] 
 Six hundred six (96.8%) of the 626 tested were characterized as A/Perth/16/2009-
like, the influenza A (H3N2) component of the 2010-11 influenza vaccine for the 
Northern Hemisphere. Twenty viruses (3.2%) of the 626 tested showed reduced 
titers with antiserum produced against A/Perth/16/2009. 
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Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [489] 
Victoria Lineage [461] 
 Four hundred sixty-one (94.3%) of the 489 influenza B viruses tested belong to the 
B/Victoria lineage of viruses. 
o Four hundred sixty (99.8%) of these 461 viruses were characterized as 
B/Brisbane/60/2008-like, the recommended influenza B component for the 
2010-11 Northern Hemisphere influenza vaccine. 
o One (0.2%) of these 461 viruses showed somewhat reduced titers with 
antisera produced against B/Brisbane/60/2008. 
Yamagata Lineage [28] 
 Twenty-eight (5.7%) of the 489 viruses were identified as belonging to the 
B/Yamagata lineage of viruses. 
Antiviral Resistance: Testing of 2009 influenza A (H1N1), influenza A (H3N2), and influenza B 
virus isolates for resistance to neuraminidase inhibitors (oseltamivir and zanamivir) is performed at 
CDC using a functional assay. Additional 2009 influenza A (H1N1) clinical samples are tested for a 
single known mutation in the neuraminidase protein of the virus that confers oseltamivir resistance 
(H275Y). The data summarized in the table below combine the results of both test methods and 
include samples that were tested as part of routine surveillance purposes; it does not include 
diagnostic testing specifically done because of clinical suspicion of antiviral resistance. 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 
influenza A (H1N1) and A (H3N2) viruses (the adamantanes are not effective against influenza B 
viruses) circulating globally. As a result of the sustained high levels of resistance, data from 
adamantane resistance testing are not presented weekly in the table below.    
Neuraminidase Inhibitor Resistance Testing Results 
on Samples Collected Since October 1, 2010. 
 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Oseltamivir Zanamivir 
Seasonal 
Influenza A 
(H1N1) 
0 0 (0.0) 0 0 (0.0) 
Influenza A 
(H3N2) 
490 0 (0.0) 490 0 (0.0) 
Influenza B 474 0 (0.0) 474 0 (0.0) 
2009 
Influenza A 
(H1N1) 
910 7 (0.8) 305 0 (0.0) 
 
Additional neuraminidase inhibitor resistance testing is performed by a subset of public health 
laboratories and results of this testing are shared with CDC. Currently, public health laboratories 
from six states (CA, ME, MD, MN, TX, and WA) have submitted results of testing performed on 
specimens collected since October 1, 2010, and seven (0.8%) of the 907 2009 influenza A (H1N1) 
specimens tested indicated resistance to oseltamivir. The specimens tested are from six states and 
may not be nationally representative. 
 
To prevent the spread of antiviral resistant virus strains, CDC reminds clinicians and the public of 
the need to continue hand and cough hygiene measures for the duration of any symptoms of 
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influenza, even while taking antiviral medications. Additional information on antiviral 
recommendations for treatment and chemoprophylaxis of influenza virus infection is available at 
http://www.cdc.gov/flu/antivirals/index.htm.   
  
 
Pneumonia and Influenza (P&I) Mortality Surveillance: During week 12, 8.7% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
above the epidemic threshold of 8.0% for week 12 and is the ninth consecutive week in which P&I 
has been at or above the epidemic threshold. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending 3/26/2011 
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Influenza-Associated Pediatric Mortality: Twelve influenza-associated pediatric deaths were 
reported to CDC during week 12. Four of these deaths were associated with influenza B viruses, 
four were associated with 2009 influenza A (H1N1) virus, one was associated with influenza A 
(H3N2) viruses, and three were associated with an influenza A virus for which the subtype was not 
determined. 
 
Eighty-nine deaths from 32 states (Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, 
Indiana, Kentucky, Louisiana, Maine, Michigan, Minnesota, Missouri, Nevada, New Jersey, New 
Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South 
Dakota, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin), Chicago, and 
New York City have been reported during this influenza season. Thirty-three of the 89 deaths 
reported were associated with influenza B viruses; 21 were associated with 2009 influenza A 
(H1N1) viruses; 17 deaths reported were associated with influenza A (H3N2) viruses, and 18 were 
associated with an influenza A virus for which the subtype was not determined.   
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2007-08 season to present 
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Week of Death
2007-08
Number of Deaths 
Reported = 88
2008-09
Number of Deaths 
Reported = 133
2009-10
Number of Deaths 
Reported = 282
Deaths Reported Current WeekDeaths Reported Previous Week
2010-11
Number of Deaths 
Reported =  89
 
 
Influenza-Associated Hospitalizations: FluSurv-NET conducts population-based surveillance for 
laboratory-confirmed influenza-associated hospitalizations in children (persons younger than 18 
years) and adults. The current network covers over 80 counties in the 10 Emerging Infections 
Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, and TN) and six additional states 
(ID, MI, OH, OK, RI, and UT). 
 
The current season’s rates include cases from October 1, 2010 to March 26, 2011. 
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Please note the following: (i) The scale of the vertical axis on the Cumulative Hospitalization Rate figures will be adjusted 
during the season to make the graphs easier to read; (ii) FluSurv-NET was created during the 2009-2010 season when 
surveillance in six states was added to ongoing surveillance for influenza-associated hospitalizations in10 EIP states. 
During the 2009-2010 season, FluSurv-NET included sites in the 10 EIP sites and sites in IA, ID, MI, ND, OK, and SD; (iii) 
the 2008-2009 EIP season ended April 14, 2009, due to the onset of the 2009 H1N1 pandemic. 
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1
Asthma may include a diagnosis of asthma and reactive airway disease; Cardiovascular diseases may include conditions 
such as coronary heart disease, cardiac valve disorders, congestive heart failure, pulmonary hypertension, and aortic 
stenosis; Chronic lung diseases may include conditions such as bronchiolitis obliterans, chronic aspiration pneumonia, 
and interstitial lung disease; Immune suppression may include conditions such as immunoglobulin deficiency, leukemia, 
lymphoma, HIV/AIDS, and individuals taking immunosuppressive medications; Metabolic disorders may include conditions 
such as diabetes mellitus, thyroid dysfunction, adrenal insufficiency, and liver disease; Neurologic diseases may include 
conditions such as seizure disorders, neuromuscular disorders, and cognitive dysfunction; Obesity was defined as a body 
mass index (BMI) greater than 30 kg/m
2
 in patients 20 years of age or older, or equal to or greater than the 95
th
 percentile 
of a patient’s age and sex category in patients under 20 years of age; Renal diseases may include conditions such as 
acute or chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance. 
2
Data as of March 29, 2011. Includes 2,778 (of a total 5,298 reported) cases for which data collection has been completed 
through the medical chart review stage. 
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Demographic and clinical characteristics of laboratory-confirmed, influenza-
associated hospitalizations identified in EIP1 and FluSurv-NET2 sites, 2006-2011 
  2010-2011 
FluSurv-NET
3
 
N (%) 
2009-2010 
FluSurv-NET 
N (%) 
2008-2009 
EIP 
N (%) 
2007-2008 
EIP 
N (%) 
2006-2007 
EIP 
N (%) 
Total Cases 5,298 7,517 1,698 3,930 1,279 
Age in Years           
0-4 825 (15.6) 1,326 (17.6) 549 (32.3) 639 (16.3) 393 (30.7) 
5-17 385 (7.3) 1,204 (16.0) 244 (14.4) 221 (5.6) 130 (10.2) 
18-49 1,344 (25.4) 2,779 (37.0) 374 (22.0) 736 (18.7) 246 (19.2) 
50-64 1,013 (19.1) 1,458 (19.4) 201 (11.8) 585 (14.9) 155 (12.1) 
65+ 1,728 (32.6) 750 (10.0) 330 (19.4) 1,749 (44.5) 355 (27.8) 
Sex           
Male 2,459 (46.4) 3,517 (46.8) 832 (49.0) 1,825 (46.4) 631 (49.3) 
Female 2,830 (53.4) 4,000 (53.2) 866 (51.0) 2,104 (53.5) 648 (50.7) 
Flu Type and Subtype           
Influenza A 4,355 (82.2) 7,355 (97.8) 1,236 (72.8) 2,562 (65.2) 1,082 (84.6) 
       Specimens subtyped
4
 1,198 5,325 -- -- -- 
            A (H1) 0 (0.0) 0 (0.0) -- -- -- 
            A (H3) 793 (66.2) 3 (0.1) -- -- -- 
            A (2009 H1N1) 405 (33.8) 5,322 (99.9) -- -- -- 
Influenza B 807 (15.2) 52 (0.7) 382 (22.5) 1,199 (30.5) 149 (11.6) 
Intensive Care Unit 466 (16.8) 1,560 (20.8) 298 (17.6) 495 (12.6) 198 (15.5) 
Mechanical Ventilation 198 (7.1) 758 (10.1) 157 (9.2) 252 (6.4) 111 (8.7) 
Diagnosis of Pneumonia 750 (27.0) 2,804 (37.3) 407 (24.0) 1,220 (31.0) 404 (31.6) 
Died 63 (2.3) 222 (3.0) 49 (2.9) 104 (2.6) 24 (1.9) 
 
Columns may not sum to 100% due to missing or unknown values. 
1
Surveillance in EIP states (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) was conducted from 2006-2011. 
2
FluSurv-Net includes surveillance at EIP sites and at sites in additional states (IA, ID, MI, ND, OK, SD in 2009-2010; ID, 
MI, OH, OK, RI, UT in 2010-2011). 
3
Data as of March 29, 2011. Results describing influenza A subtype, intensive care unit admission, mechanical ventilation, 
diagnosis of pneumonia, and death are from 2,778 (of a total 5,298 reported) cases for which data collection has been 
completed through the medical chart review stage. 
4
Influenza A subtype results are available beginning with the 2007-2008 season. Percentages for influenza A subtypes 
are calculated using the number of influenza A specimens that were subtyped as a denominator. 
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Outpatient Illness Surveillance: Nationwide during week 12, 2.0% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI). This percentage is below the national baseline of 2.5%.  
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, September 30, 2007 – March 26, 2011 
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On a regional level, the percentage of outpatient visits for ILI ranged from 1.0% to 3.2% during 
week 12. Two of the 10 regions (Regions 2 and 10) reported ILI at or above region-specific baseline 
levels. 
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Region 4 - AL, FL, GA, KY, MS, NC, SC, TN
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Region 5 - IL, IN, MI, MN, OH, WI
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Region 7 - IA, KS, MO, NE
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Region 8 - CO, MT, ND, SD, UT, WY
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Region 9 - AZ, CA, HI, NV
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Region 10 - AK, ID, OR, WA
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NOTE: Scales differ between regions
*Use of the regional baselines for state data is not appropriate. 
Baseline*% ILI
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ILINet State Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during spring and fall weeks with 
little or no influenza virus circulation. Activity levels range from minimal, which would correspond to 
ILI activity from outpatient clinics being below the average, to high, which would correspond to ILI 
activity from outpatient clinics being much higher than the average. Because the clinical definition of 
ILI is very general, not all ILI is caused by influenza; however, when combined with laboratory data, 
the information on ILI activity provides a clear picture of influenza activity in the United States. 
 
During week 12, the following ILI activity levels were experienced: 
 One state (Idaho) experienced high ILI activity. 
 Three states (Alaska, Illinois, and North Dakota) experienced low ILI activity. 
 Minimal ILI activity was experienced by New York City and 46 states (Alabama, Arizona, 
Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, 
Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New 
Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, 
South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, 
West Virginia, Wisconsin, and Wyoming). 
 The District of Columbia had insufficient data to calculate an activity level. 
 
Interactive web tool available at: http://gis.cdc.gov/grasp/fluview/main.html 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a state. It does not, 
however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high 
activity levels. 
Data collected in ILINet may disproportionately represent certain populations within a state, and therefore, may not accurately depict the full picture of 
influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and 
territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received. 
Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the 
state likely being the more complete.  
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the severity of influenza activity. 
 
During week 12, the following influenza activity was reported: 
 Widespread influenza activity was reported by ten states (Alaska, Connecticut, Idaho, 
Maine, Minnesota, Montana, Nevada, New Hampshire, New York, and Virginia). 
 Regional influenza activity was reported by 22 states (Arizona, California, Colorado, 
Georgia, Hawaii, Iowa, Louisiana, Maryland, Massachusetts, Michigan, Missouri, New 
Jersey, New Mexico, North Dakota, Ohio, Pennsylvania, South Carolina, South Dakota, 
Vermont, Washington, Wisconsin, and Wyoming). 
 Local influenza activity was reported by the District of Columbia and 12 states (Alabama, 
Arkansas, Illinois, Kansas, Kentucky, Mississippi, Nebraska, Oklahoma, Tennessee, Texas, 
Utah, and West Virginia). 
 Sporadic influenza activity was reported by Guam, Puerto Rico, the U.S. Virgin Islands, and 
six states (Delaware, Florida, Indiana, North Carolina, Oregon, and Rhode Island). 
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Additional National and International Influenza Surveillance Information 
 
Distribute Project: Additional information on the Distribute syndromic surveillance project, 
developed and piloted by the International Society for Disease Surveillance (ISDS), now working in 
collaboration with CDC to enhance and support Emergency Department (ED) surveillance, is 
available at http://isdsdistribute.org/. 
 
Google Flu Trends: Google Flu Trends uses aggregated Google search data in a model created in 
collaboration with CDC to estimate influenza activity in the United States. For more information and 
activity estimates from the U.S. and worldwide, see http://www.google.org/flutrends/. 
 
Europe: For the most recent influenza surveillance information from Europe, please see 
WHO/Europe at http://www.euroflu.org/index.php and visit the European Centre for Disease 
Prevention and Control at 
http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_survei
llance_overview.aspx. 
 
Public Health Agency of Canada: The most up to date influenza information from Canada is 
available at http://www.phac-aspc.gc.ca/fluwatch/. 
 
World Health Organization FluNet: Additional influenza surveillance information from participating 
WHO member nations is available at http://gamapserver.who.int/GlobalAtlas/home.asp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/overview.htm 
Report prepared: April 1, 2011. 
